China Resources Double-Crane Pharmaceutical (SHA:600062) received a drug registration certificate from China's National Medical Products Administration for its lomustine capsules, according to a Wednesday filing with the Shanghai bourse.
The capsules are indicated for children and adult patients with primary malignant brain tumors following surgery and radiotherapy, according to the drugmaker.
Shares in the drugmaker slipped 1% during afternoon trading on Wednesday.